Original research article| Volume 85, ISSUE 2, P211-214, February 2012

Mifepristone may shorten the induction-to-abortion time for termination of second-trimester pregnancies by ethacridine lactate



      We reviewed our experience with adding mifepristone to the protocol for the termination of pregnancy up to 24 weeks of gestation by intra-amniotic ethacridine lactate.

      Study Design

      The study consisted of women who presented for the termination of a second-trimester pregnancy between August 2000 and July 2008.


      Of 1245 women who requested a termination of a second-trimester pregnancy, 744 women underwent the induction of abortion by intra-amniotic ethacridine lactate with mifepristone (mifepristone group), and 501 received intra-amniotic ethacridine lactate alone (control group). The proportion of women who delivered within 24 h was 25.94% in the mifepristone group and 10.18% in the control group (p<.001); the failure rate of abortion was 5.38% in the mifepristone group and 4.99% in the control group (p<.001). There was no significant difference in the complication rate between the two groups. The rate of cervical laceration was 0.54% in the mifepristone group and 0.60% in the control group (p=.9315). The rate of retained placental tissue was 6.99% in the mifepristone group and 6.19% in the control group (p=.1112). Nausea was reported by 34.0% of women in the mifepristone group and none in the control group.


      The addition of mifepristone to ethacridine lactate may shorten the induction-to-abortion time compared with the use of ethacridine lactate alone without increasing the number of complications.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. World Health Organization medical methods for termination of pregnancy. WHO technical report series 871. World Health Organization, Geneva1997
        • Bygdeman M.
        • Swahn M.L.
        Progesterone receptor blockage. Effect on uterine contractility and early pregnancy.
        Contraception. 1985; 32: 45-51
        • Urquhart D.R.
        • Templeton A.A.
        Mifepristone (RU 486) and second-trimester termination.
        Lancet. 1987; 2: 1405
        • Swahn M.L.
        • Bygdeman M.
        The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin.
        Br J Obstet Gynaecol. 1988; 95: 126-134
        • Silvestre L.
        • Dubois C.
        • Renault M.
        • Rezvani Y.
        • Baulieu E.E.
        • Ulmann A.
        Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience.
        N Engl J Med. 1990; 322: 645-648
        • Gottlieb C.
        • Bygdeman M.
        The use of antiprogestin (RU 486) for termination of second trimester pregnancy.
        Acta Obstet Gynecol Scand. 1991; 70: 199-203
        • Tien K.H.
        Intraamniotic injection of ethacridine for second-trimester induction of labor.
        Obstet Gynecol. 1983; 61: 733-736
        • Berg C.
        • Ludwig M.
        • Sturm N.
        • Diedrich K.
        • Gembruch U.
        • Geipel A.
        Intraamniotic ethacridine lactate instillation versus vaginal PGE1 in second trimester termination of pregnancy.
        Eur J Obstet Gynecol Reprod Biol. 2006; 126: 193-196
        • Schreiber C.
        • Creinin M.
        Mifepristone in abortion care.
        Semin Reprod Med. 2005; 23: 82-91
        • Neilson J.P.
        Mifepristone for induction of labour (Cochrane Review).
        Cochrane Library. 2000; (Oxford: CD002865)
        • Tang O.S.
        • Ho P.C.
        The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion.
        Contraception. 2006; 74: 26-30
        • Toppozada M.
        • Ismail A.A.
        Intrauterine administration of drugs for termination of pregnancy in the second trimester.
        Baillieres Clin Obstet Gynaecol. 1990; 4: 327-349
        • Olund A.
        • Kindahl H.
        • Oliw E.
        • Lindgren J.A.
        • Larsson B.
        Prostaglandins and thromboxanes in amniotic fluid during rivanol-induced abortion and labour.
        Prostaglandins. 1980; 19: 791-803
        • Keirse M.J.
        • Hicks B.R.
        • Mitchell M.D.
        • Turnbull A.C.
        Increase of the prostaglandin precursor, arachidonic acid, in amniotic fluid during spontaneous labour.
        Br J Obstet Gynaecol. 1977; 84: 937-940
        • Rudolph M.I.
        • Cabanillas A.
        • Gomez P.
        • Garcia M.A.
        • Villan L.
        On the mechanism of action of ethodin in inducing myometrium contractions.
        Gen Pharmacol. 1997; 28: 381-385
        • Clark K.
        • Ji H.L.
        • Feltovich H.
        • Janowski J.
        • Carroll C.
        • Chien E.K.
        Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events.
        Am J Obstet Gynecol. 2006; 194: 1391-1398
        • Tang O.S.
        • Thong K.J.
        • Baird D.T.
        Second trimester medical abortion with mifepristone and gemeprost: a review of 956 cases.
        Contraception. 2001; 64: 29-32